Sarcopenia research and clinical management

Research and medical expertise regarding sarcopenia, the age-related loss of muscle mass and strength, have highlighted both its biological mechanisms and clinical management.

Scientific studies published in Aging Cell indicate that sarcopenia stems from disrupted communication between various cell types, such as muscle stem, immune, and nerve cells. In older mice, the protein NDRG1 was observed to inhibit the mTOR signaling pathway, preventing muscle stem cells from returning to a resting state. Furthermore, in patients with Chronic Obstructive Pulmonary Disease (COPD), the enzyme Prodh2 has been linked to muscle damage via the cGAS/STING signaling pathway.

Clinical perspectives emphasize that sarcopenia typically affects individuals over age 60, increasing risks for falls, fractures, and reduced mobility. Experts note that skeletal muscles act as endocrine organs by releasing myokines that regulate glucose and fatty acid oxidation. Risk factors for the condition include hormonal changes, chronic inflammation, nutritional deficiencies, and sedentary lifestyles. Muscle mass and function can be assessed through imaging technologies like DEXA or MRI, as well as functional tests measuring grip strength and walking speed.